What Is Low-Dose Naltrexone? Uses, Evidence, and Safety
Low-dose naltrexone—often called LDN—has become an increasingly discussed option among patients living with persistent pain, fibromyalgia, and certain chronic inflammatory or neurologic conditions. The interest is understandable: some early trials and reviews suggest potential benefits for selected patients.
But LDN is not a proven cure, it is not appropriate for everyone, and it has an especially important interaction with opioid medications. The best way to understand LDN is to separate what is established from what is still being studied.
What Is Low-Dose Naltrexone?
Naltrexone is a prescription opioid antagonist, meaning it binds to opioid receptors and blocks opioid effects. FDA-approved oral naltrexone tablets are commonly supplied at 50 mg and are indicated as part of the treatment of alcohol dependence and for blocking the effects of externally administered opioids. Review the FDA-approved prescribing information through DailyMed.
“Low-dose naltrexone” describes clinician-directed use at a dose below the standard 50 mg tablet. There is no single FDA-defined LDN dose or FDA-approved LDN indication. When naltrexone is prescribed at a lower dose for pain, fibromyalgia, or other conditions, that use is considered off-label.
Off-label prescribing is a recognized part of medical practice, but it requires an individualized clinical decision. It does not mean that FDA has reviewed and approved the medication as safe and effective for that particular condition.
Why Are Clinicians Interested in LDN?
Researchers have proposed that low-dose exposure may affect pain signaling and neuroinflammatory pathways differently from standard-dose naltrexone. These mechanisms remain an active area of investigation and should not be treated as proof of clinical benefit.
Clinicians may discuss LDN with selected patients experiencing:
- Fibromyalgia or centralized pain symptoms
- Other forms of persistent pain
- Symptoms associated with certain inflammatory or neurologic conditions
- A need for an individualized dosage form that is not commercially available
These are areas of clinical interest—not a list of FDA-approved uses or a promise that LDN will help every condition.
What Does the Research Show?
Fibromyalgia and persistent pain
Fibromyalgia has received much of the recent LDN research attention. Small randomized trials and subsequent reviews have produced mixed but potentially encouraging findings.
Some analyses report reductions in pain compared with placebo, while individual trials differ in design, dose, duration, and outcomes. Recent research includes a randomized crossover trial, a 2024 randomized placebo-controlled trial, and a systematic review and meta-analysis.
The practical conclusion is measured: LDN may be a reasonable topic for a patient and prescriber to discuss, but current evidence does not establish it as a universally effective fibromyalgia treatment.
Larger, well-designed trials are still needed to clarify who is most likely to benefit and what treatment approach is most appropriate.
Multiple sclerosis and other chronic conditions
Small studies in multiple sclerosis have examined safety, tolerability, and quality-of-life measures. Findings have not established LDN as a disease-modifying therapy, and it should not be presented as a substitute for established MS treatment.
A 2010 pilot trial reported changes in selected quality-of-life measures, while another randomized study concluded that efficacy remained uncertain.
Research into other inflammatory, gastrointestinal, and chronic pain conditions remains limited or preliminary. A positive early study is a reason for further research—not proof that a medication treats every condition linked to inflammation.
Is Low-Dose Naltrexone FDA-Approved?
Naltrexone itself is FDA-approved for specific uses at standard dosing, but LDN for chronic pain, fibromyalgia, autoimmune symptoms, or similar conditions is off-label.
When a pharmacy compounds an individualized LDN dosage form, the finished compounded medication is also not FDA-approved. The FDA explains that compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before they are marketed.
However, compounding can serve an important medical need for an individual patient when an FDA-approved product does not meet that patient’s needs. Learn more about compounded medications from the FDA.
That distinction should be transparent: a compounded medication is prepared pursuant to a prescription for an identified patient; it is not an FDA-approved generic equivalent.
The Most Important Safety Question: Do You Use Opioids?
Naltrexone blocks opioid receptors. It is contraindicated for people currently receiving opioid analgesics, people with current physiological opioid dependence, and people in acute opioid withdrawal.
Starting naltrexone too soon after opioid use can precipitate sudden withdrawal, which may be severe. DailyMed provides the complete contraindications and warnings.
Before taking LDN, tell your prescriber and pharmacist about every medicine you use, including:
- Prescription opioid pain medicines
- Tramadol
- Buprenorphine or methadone
- Opioid-containing cough, cold, or diarrhea products
- Any recent nonprescribed opioid use
- Planned surgery or a procedure that may require pain control
Do not stop an opioid or decide when to start LDN on your own. The necessary opioid-free interval depends on the medicine, pattern of use, and individual clinical circumstances. Your treating clinician should make that decision.
Naltrexone may also change how opioid pain treatment works during an emergency or procedure. Make sure every treating clinician knows that you take LDN.
What Side Effects Should Patients Discuss?
Naltrexone labeling includes possible effects such as:
- Nausea
- Headache
- Dizziness
- Fatigue
- Sleep-related symptoms
- Abdominal discomfort
Liver injury has also been reported. Patients should promptly contact a clinician if they experience symptoms such as persistent abdominal pain, dark urine, or yellowing of the skin or eyes.
Your prescriber may consider your liver history, kidney function, pregnancy or breastfeeding status, mental health, upcoming procedures, and other medications before recommending treatment.
Side effects and monitoring needs can differ from person to person.
Why Might a Prescriber Order Compounded LDN?
The commercially available 50 mg tablet may not match a prescriber’s desired strength for low-dose therapy. A compounding pharmacy can prepare a patient-specific prescription in a strength or dosage form selected by the prescriber when clinically appropriate.
A pharmacist can also help:
- Review the prescription for clarity and potential medication conflicts
- Discuss how to store and take the prescribed preparation
- Identify questions that should go back to the prescriber
- Coordinate refills and reinforce safe medication use
Compounding does not turn an off-label use into an FDA-approved one, and individualized preparation does not guarantee effectiveness. Its role is to help meet a patient-specific prescription need.
Questions to Ask Before Starting LDN
Bring these questions to your clinician or pharmacist:
- What symptom or treatment goal are we targeting?
- How strong is the evidence for LDN in my condition?
- Could any of my medicines contain an opioid or interact with naltrexone?
- What should I do if I need surgery, emergency care, or opioid pain treatment?
- What side effects should prompt a call?
- How and when will we decide whether treatment is helping?
The Bottom Line
LDN is a promising but still evolving off-label treatment approach. Evidence is more developed in some pain conditions than in others, yet important uncertainties remain.
It deserves a thoughtful conversation—not a cure claim.
The safest next step is a complete medication review with a qualified prescriber and pharmacist, especially if you use or recently used any opioid-containing medication.
Talk With Scripx Pharmacy
Have a prescription for individualized low-dose naltrexone or questions about a prescribed compounded preparation?
Contact Scripx Pharmacy to speak with the pharmacy team about prescription requirements, medication review, formulation options, and service availability. A licensed prescriber must determine whether LDN is appropriate for you.
This article is for general education and does not replace individualized medical advice. Low-dose naltrexone uses described here are off-label. Compounded medications are not FDA-approved.
Frequently Asked Questions
Is LDN the same as standard-dose naltrexone?
LDN uses the same active ingredient but at a lower, clinician-selected dose. FDA-approved oral naltrexone is commonly supplied as a 50 mg tablet for specific substance-use indications. LDN uses for pain and other chronic conditions are off-label.
Can I take LDN with opioid pain medicine?
Naltrexone can block opioid effects and may precipitate withdrawal in an opioid-dependent person. Do not combine or transition between these medicines without direct guidance from your treating clinician.
Does LDN cure fibromyalgia or autoimmune disease?
No cure claim is supported. Research suggests possible symptom benefits for some patients, particularly in fibromyalgia, but findings are mixed and further high-quality trials are needed.
Why is LDN compounded?
A prescriber may request compounding when a patient-specific strength or dosage form is not available in an FDA-approved commercial product. The resulting compounded preparation is not FDA-approved.